Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
| dc.contributor.author | Lassen, U | |
| dc.contributor.author | Chinot, O | |
| dc.contributor.author | McBain, Catherine A | |
| dc.contributor.author | Mau-Sørensen, M | |
| dc.contributor.author | Larsen, V | |
| dc.contributor.author | Barrie, M | |
| dc.contributor.author | Roth, P | |
| dc.contributor.author | Krieter, O | |
| dc.contributor.author | Wang, K | |
| dc.contributor.author | Habben, K | |
| dc.contributor.author | Tessier, J | |
| dc.contributor.author | Lahr, A | |
| dc.contributor.author | Weller, M | |
| dc.date.accessioned | 2015-02-25T11:57:20Z | |
| dc.date.available | 2015-02-25T11:57:20Z | |
| dc.date.issued | 2015-02-09 | |
| dc.identifier.citation | Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. 2015: Neuro-oncology | en |
| dc.identifier.issn | 1523-5866 | |
| dc.identifier.pmid | 25665807 | |
| dc.identifier.doi | 10.1093/neuonc/nov019 | |
| dc.identifier.uri | http://hdl.handle.net/10541/345296 | |
| dc.description.abstract | We conducted a phase 1 dose-escalation study of RO5323441, a novel antiplacental growth factor (PlGF) monoclonal antibody, to establish the recommended dose for use with bevacizumab and to investigate the pharmacokinetics, pharmacodynamics, safety/tolerability, and preliminary clinical efficacy of the combination. | |
| dc.language | ENG | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Neuro-oncology | en |
| dc.title | Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. | en |
| dc.type | Article | en |
| dc.contributor.department | Department of Oncology, Rigshospitalet, Copenhagen, Denmark | en |
| dc.identifier.journal | Neuro-oncology | en |
| html.description.abstract | We conducted a phase 1 dose-escalation study of RO5323441, a novel antiplacental growth factor (PlGF) monoclonal antibody, to establish the recommended dose for use with bevacizumab and to investigate the pharmacokinetics, pharmacodynamics, safety/tolerability, and preliminary clinical efficacy of the combination. |